March 05, 2013 at 15:05 PM EST
UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns
JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA ) with a Neutral rating and lowered the price target from $8.00 to $7.00. JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here